DenmarkTuberculosis profile
Population  2014 5.6 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.024 (0.023–0.025) 0.42 (0.4–0.45)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.01–0.03)
Prevalence  (includes HIV+TB) 0.5 (0.21–0.91) 8.9 (3.7–16)
Incidence  (includes HIV+TB) 0.4 (0.35–0.45) 7.1 (6.2–8)
Incidence (HIV+TB only) 0.012 (<0.01–0.015) 0.22 (0.17–0.27)
         
Case detection, all forms (%) 73 (65–84)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.51 (0.01–2.8) 5 (0.13–25)
MDR-TB cases among notified pulmonary
TB cases
1 (0–6) 1 (0–7)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 200    
Pulmonary, clinically diagnosed 26    
Extrapulmonary 67    
       
Total new and relapse 293    
Previously treated, excluding relapses 27    
Total cases notified 320    
Among 293 new and relapse cases:
9 (3%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 197 (99%) 18 (67%) 215
Laboratory-confirmed RR-/MDR-TB cases     1
Patients started on MDR-TB treatment ***      
TB/HIV 2014 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (59) 329
Previously treated cases, excluding relapse, registered in 2013 (48) 25
HIV-positive TB cases, all types, registered in 2013 (43) 7
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Is second-line drug susceptibility testing available?  
Financing TB control 2015  
National TB programme budget (US$ millions)  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-06 Data: www.who.int/tb/data